Cargando…
G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future
Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer es...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Chinese Anti-Cancer Association
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372908/ https://www.ncbi.nlm.nih.gov/pubmed/30766748 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0030 |